In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia

@article{Bossert:2020aa,

title = {In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia},

author = {Jennifer M Bossert and Eugene A Kiyatkin and Hannah Korah and Jennifer K Hoots and Anum Afzal and David Perekopskiy and Shruthi Thomas and Ida Fredriksson and Bruce E Blough and Stevens S Negus and David H Epstein and Yavin Shaham},

url = {https://pubmed.ncbi.nlm.nih.gov/32305216/},

doi = {10.1016/j.biopsych.2020.02.014},

isbn = {0006-3223},

year  = {2020},

date = {2020-12-15},

urldate = {2020-12-15},

booktitle = {Biological Psychiatry},

journal = {Biological Psychiatry},

volume = {88},

number = {12},

pages = {935--944},

publisher = {Elsevier},

abstract = {BackgroundMaintenance treatment with opioid agonists (buprenorphine, methadone) is effective for opioid addiction but does not eliminate opioid use in all patients. We modeled maintenance treatment in rats that self-administered the prescription opioid oxycodone. The maintenance medication was either buprenorphine or the G protein?biased mu opioid receptor agonist TRV130. We then tested prevention of oxycodone seeking and taking during abstinence using a modified context-induced reinstatement procedure, a rat relapse model.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}